Long term effects of dichloromethylene diphosphonate in Paget's disease of bone.
Dichloromethylene diphosphonate (Cl2MDP) is a diphosphonate which markedly inhibits bone resorption. We have tested Cl2MDP in Paget's disease, a disorder characterized by increased bone remodeling. Sixty-three patients with progressive Paget's disease were treated for 6 months with Cl2MDP at daily oral doses of 400, 800, 1600, or 2400 mg. Thirty-nine patients received calcium and vitamin D supplements during treatment. patients in all treatment groups had significant reduction in serum alkaline phosphatase, urinary hydroxyproline, skeletal uptake of 99mtechnetium-diphosphonate scintiscans, and resorption parameters on iliac crest biopsy samples as assessed by quantitative histomorphometry. Treatment was well tolerated and did not induce a skeletal mineralization defect. The reduction in alkaline phosphatase and urinary hydroxyproline persisted 1 yr after withdrawal of treatment. The biochemical remission was sustained in half of the patients 2 yr after the end of treatment and was accompanied by a marked reduction of bone pain. a daily dose of 800 mg is recommended as the best of control of clinical and biochemical symptoms. The transient increase in iPTH levels observed in patients treated with Cl2MDP alone did not occur when calcium and vitamin D were added. We conclude that Cl2MDP is effective in the treatment of Paget's disease of bone and provides a prolonged response. Dietary supplementation with calcium and vitamin D is desirable to prevent secondary hyperparathyroidism.
D000469:Alkaline Phosphatase / Q000097:blood; D001862:Bone Resorption / Q000187:drug effects; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002118:Calcium / Q000627:therapeutic use; D004002:Clodronic Acid / Q000008:administration & dosage / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D006962:Hyperparathyroidism, Secondary / Q000209:etiology; D010001:Osteitis Deformans / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D011877:Radionuclide Imaging; D014807:Vitamin D / Q000627:therapeutic use
D004164:Diphosphonates; D010281:Parathyroid Hormone; D004002:Clodronic Acid; D014807:Vitamin D; D000469:Alkaline Phosphatase; D006909:Hydroxyproline; D002118:Calcium